Jennifer S Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3953627/publications.pdf

Version: 2024-02-01

		201674	69250
83	6,604	27	77
papers	citations	h-index	g-index

85	85	85	6890
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. Journal of Clinical Pharmacology, 2022, 62, 220-231.	2.0	7
2	A systematic review of the evidence supporting post-operative antithrombotic use following cardiopulmonary bypass in children with CHD. Cardiology in the Young, 2022, 32, 10-20.	0.8	1
3	Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. Circulation, 2022, 145, 345-356.	1.6	132
4	Causes of Death in Infants and Children with Congenital Heart Disease. Pediatric Cardiology, 2021, 42, 1308-1315.	1.3	8
5	Individuals aged 1-64 years with documented congenital heart defects at healthcare encounters, five U.S. surveillance sites, 2011-2013. American Heart Journal, 2021, 238, 100-108.	2.7	10
6	Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms. Journal of Pediatrics, 2021, , .	1.8	2
7	Weight-Related Behaviors of Children with Obesity during the COVID-19 Pandemic. Childhood Obesity, 2021, 17, 371-378.	1.5	54
8	Thromboprophylaxis for Children Postâ€Fontan Procedure: Insights From the UNIVERSE Study. Journal of the American Heart Association, 2021, 10, e021765.	3.7	32
9	Risk Factors for Sudden Infant Death in North Carolina. Frontiers in Pediatrics, 2021, 9, 770803.	1.9	2
10	The Bayley-III scale may underestimate neurodevelopmental disability after cardiac surgery in infants. European Journal of Cardio-thoracic Surgery, 2020, 57, 63-71.	1.4	13
11	A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery. Pediatric Critical Care Medicine, 2020, 21, e795-e803.	0.5	10
12	Clinical and socio-economic predictors of work participation in adult CHD patients. Cardiology in the Young, 2020, 30, 1081-1085.	0.8	4
13	Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. Journal of Pediatrics, 2020, 222, 213-220.e5.	1.8	8
14	Pulmonary Valve Endocarditis: The Potential Utility of Multimodal Imaging Prior to Surgery. World Journal for Pediatric & Congenital Heart Surgery, 2020, 11, 192-197.	0.8	3
15	Rationale and design of â€œHearts & Parksâ€• study protocol for a pragmatic randomized clinical trial of an integrated clinic-community intervention to treat pediatric obesity. BMC Pediatrics, 2020, 20, 308.	1.7	6
16	Flattening the (BMI) Curve: Timing of Child Obesity Onset and Cardiovascular Risk. Pediatrics, 2020, 146, e20201353.	2.1	4
17	Behavior and Quality of Life at 6 Years for Children With Hypoplastic Left Heart Syndrome. Pediatrics, 2019, 144, .	2.1	25
18	Acid Suppression Therapy and Symptom Improvement (or Lack Thereof) in Children. Pediatrics, 2019, 144, e20190909.	2.1	3

#	Article	IF	Citations
19	Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children postâ€“Fontan procedure: Rationale and design of a prospective, randomized trial (the) Tj ETQq1 1 0.784314 rgBT /Overlock	2.1	0
20	Research Gaps in Primary Pediatric Hypertension. Pediatrics, 2019, 143, .	2.1	23
21	Agreement of an echocardiogram-based diagnosis of pulmonary hypertension in infants at risk for bronchopulmonary dysplasia among masked reviewers. Journal of Perinatology, 2019, 39, 248-255.	2.0	17
22	Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multiâ€Stakeholder Think Tank. Journal of the American Heart Association, 2018, 7, .	3.7	23
23	Severe Cardiac Involvement Is Rare in Patients with Late-Onset Pompe Disease and the Common c.-32-13T>G Variant: Implications for Newborn Screening. Journal of Pediatrics, 2018, 198, 308-312.	1.8	21
24	Effect of renal function on antihypertensive drug safety and efficacy in children. Pediatric Nephrology, 2018, 33, 139-146.	1.7	5
25	Changes in Drug Development Regulations and Their Impact on Clinical Trials. , 2018, , 841-852.		0
26	Impact of imaging approach on radiation dose and associated cancer risk in children undergoing cardiac catheterization. Catheterization and Cardiovascular Interventions, 2017, 89, 888-897.	1.7	14
27	Congenital Heart Disease in Premature Infants 25-32 Weeks' Gestational Age. Journal of Pediatrics, 2017, 181, 37-41.e1.	1.8	46
28	Maladaptive aortic properties after the Norwood procedure: An angiographic analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 471-479.e3.	0.8	14
29	Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with Late-Onset Pompe Disease: A Case Report. JIMD Reports, 2016, 31, 79-83.	1.5	20
30	Cardiopulmonary resuscitation in hospitalized infants. Early Human Development, 2016, 101, 17-22.	1.8	13
31	Childhood Hypertension: An Underappreciated Epidemic?. Pediatrics, 2016, 138, e20162857-e20162857.	2.1	10
32	Cliniciansâ€™ Adherence to Guidelines on Evaluation of Hypertension in Children and Adolescents. World Journal for Pediatric & Congenital Heart Surgery, 2016, 7, 440-445.	0.8	2
33	Changes in Drug Development Regulations and Their Impact on Clinical Trials. , 2016, , 1-12.		0
34	Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database. Cardiology in the Young, 2015, 25, 172-180.	0.8	12
35	Neurodevelopmental Outcomes After Cardiac Surgery in Infancy. Pediatrics, 2015, 135, 816-825.	2.1	392
36	Response to Letters Regarding Article, â€œCumulative Radiation Exposure and Cancer Risk Estimation in Children With Heart Diseaseâ€. Circulation, 2015, 131, e419-20.	1.6	1

#	Article	IF	Citations
37	Implementation of Management Strategies for Diabetes and Hypertension: From Local to Global Health in Cardiovascular Diseases. Global Heart, 2015, 10, 31.	2.3	12
38	Cumulative Radiation Exposure and Cancer Risk Estimation in Children With Heart Disease. Circulation, 2014, 130, 161-167.	1.6	192
39	Longitudinal Assessment of Growth in Hypoplastic Left Heart Syndrome: Results From the Single Ventricle Reconstruction Trial. Journal of the American Heart Association, 2014, 3, e000079.	3.7	63
40	Comparative Effectiveness of Digoxin and Propranolol for Supraventricular Tachycardia in Infants*. Pediatric Critical Care Medicine, 2014, 15, 839-845.	0.5	18
41	Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. American Heart Journal, 2014, 167, 921-929.e2.	2.7	31
42	Excess Costs Associated With Complications and Prolonged Length of Stay After Congenital Heart Surgery. Annals of Thoracic Surgery, 2014, 98, 1660-1666.	1.3	79
43	Challenges and Priorities for Research. Circulation, 2014, 130, 1192-1203.	1.6	28
44	Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients. Clinical Investigation, 2014, 4, 989-991.	0.0	2
45	Pediatric trials of antihypertensive agents: impact of trial design and unique pediatric factors on efficacy end points. Clinical Investigation, 2014, 4, 1031-1041.	0.0	2
46	Clopidogrel in Infants with Systemic-to-Pulmonary-Artery Shunts. New England Journal of Medicine, 2013, 368, 2377-2384.	27.0	57
47	Changes in Pediatric Food and Drug Administration Written Requests and Regulations: Impact on Clinical Trial of Hypertension Trials in Children. , 2013, , 573-582.		0
48	Status of the Pediatric Clinical Trials Enterprise: An Analysis of the US ClinicalTrials.gov Registry. Pediatrics, 2012, 130, e1269-e1277.	2.1	78
49	Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: A comparative study of platelet aggregation response. Platelets, 2012, 23, 430-438.	2.3	10
50	Perioperative Methylprednisolone and Outcome in Neonates Undergoing Heart Surgery. Pediatrics, 2012, 129, e385-e391.	2.1	101
51	Opportunities and challenges in linking information across databases in pediatric cardiovascular medicine. Progress in Pediatric Cardiology, 2012, 33, 21-24.	0.4	14
52	Clinical Research Careers: Reports from a NHLBI Pediatric Heart Network Clinical Research Skills Development Conference. American Heart Journal, 2011, 161, 13-67.	2.7	9
53	Lessons learned from a pediatric clinical trial: The Pediatric Heart Network Angiotensin-Converting Enzyme Inhibition in Mitral Regurgitation Study. American Heart Journal, 2011, 161, 233-240.	2.7	27
54	Pediatric Cardiovascular Drug Trials, Lessons Learned. Journal of Cardiovascular Pharmacology, 2011, 58, 4-8.	1.9	20

#	Article	IF	Citations
55	Pediatric Antihypertensive Clinical Trials. , 2011, , 575-585.		0
56	Antiplatelet Therapy in Pediatric Cardiovascular Patients. Pediatric Cardiology, 2010, 31, 454-461.	1.3	14
57	The Efficacy and Safety of the Novel Aldosterone Antagonist Eplerenone in Children with Hypertension: A Randomized, Double-Blind, Dose-Response Study. Journal of Pediatrics, 2010, 157, 282-287.	1.8	48
58	Partial and Transitional Atrioventricular Septal Defect Outcomes. Annals of Thoracic Surgery, 2010, 89, 530-536.	1.3	47
59	Safety of Aprotinin in Congenital Heart Operations: Results from a Large Multicenter Database. Annals of Thoracic Surgery, 2010, 90, 14-21.	1.3	52
60	Platelet Activity Associated with Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Children with Cardiovascular Disease. Congenital Heart Disease, 2010, 5, 552-555.	0.2	7
61	Laboratory Measures of Exercise Capacity and Ventricular Characteristics and Function Are Weakly Associated With Functional Health Status After Fontan Procedure. Circulation, 2010, 121, 34-42.	1.6	42
62	Globalization of Pediatric Research: Analysis of Clinical Trials Completed for Pediatric Exclusivity. Pediatrics, 2010, 126, e687-e692.	2.1	40
63	Fluticasone propionate/salmeterol combination in children with asthma: Key cardiac and overall safety results. Clinical Research and Regulatory Affairs, 2010, 27, 87-95.	2.1	8
64	Safety and Transparency of Pediatric Drug Trials. JAMA Pediatrics, 2009, 163, 1080-6.	3.0	60
65	The economic returns of pediatric clinical trials of antihypertensive drugs. American Heart Journal, 2008, 156, 682-688.	2.7	23
66	Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children. Circulation, 2008, 117, 553-559.	1.6	135
67	Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity. Pediatrics, 2008, 122, e628-e633.	2.1	36
68	Pediatric Antihypertensive Trial Failures. Hypertension, 2008, 51, 834-840.	2.7	117
69	Response to Letter Regarding Article, â€œDosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trialâ€. Circulation, 2008, 118, .	1.6	0
70	Safety of Placebo Controls in Pediatric Hypertension Trials. Hypertension, 2008, 51, 829-833.	2.7	19
71	Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program. JAMA - Journal of the American Medical Association, 2007, 297, 480.	7.4	148
72	Rationale and design of a randomized clinical trial of Î²-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. American Heart Journal, 2007, 154, 624-631.	2.7	217

#	Article	IF	Citations
73	Clinical Outcomes of Palliative Surgery Including a Systemic-to-Pulmonary Artery Shunt in Infants With Cyanotic Congenital Heart Disease. Circulation, 2007, 116, 293-297.	1.6	142
74	Is pediatric exclusivity working?. Pediatric Health, 2007, 1, 43-49.	0.3	3
75	Peer-Reviewed Publication of Clinical Trials Completed for Pediatric Exclusivity. JAMA - Journal of the American Medical Association, 2006, 296, 1266.	7.4	134
76	The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Review of Cardiovascular Therapy, 2006, 4, 649-654.	1.5	34
77	Is the Extrapolated Adult Dose of Fosinopril Safe and Effective in Treating Hypertensive Children?. Hypertension, 2004, 44, 289-293.	2.7	67
78	Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. American Heart Journal, 2004, 147, 173-180.	2.7	27
79	Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. American Heart Journal, 2002, 144, 608-614.	2.7	26
80	Realâ€Time Volumetric Echocardiography. Echocardiography, 2000, 17, 773-779.	0.9	56
81	Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis. Clinical Infectious Diseases, 2000, 30, 633-638.	5.8	3,392
82	Etiology and danger of pericardial effusion in infants and children. Cardiology in the Young, 1996, 6, 162-165.	0.8	4
83	Relation of left ventricular mass, volume and mass/volume ratio in children with aortic stenosis and/or insufficiency. Cardiology in the Young, 1995, 5, 105-109.	0.8	0